Hypericin - The facts about a controversial agent

Current Pharmaceutical Design

Volumn 11, Issue 2, 2005, Pages 233-253

  Kubin, A ^a,b,d   Wierrani, F ^b,c   Burner, U ^b   Alth, G ^a,b   Grunberger W ^b,c  

^a LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^b Vienna Soc Photodynamic Diagn P   (Austria)

^c Rudolfstiftung   (Austria)

^d NONE   (Austria)

Author keywords

Antiretroviral; Antiviral; Fluorescence diagnosis; Photodynamic therapy (PDT); Photophysical diagnosis (PPD); Photosensitizer

Indexed keywords

4 AMINOBUTYRIC ACID; AMINE OXIDASE (FLAVIN CONTAINING); CYTOCHROME P450; DOPAMINE BETA MONOOXYGENASE; HEMATOPORPHYRIN; HYPERICIN; HYPERICUM PERFORATUM EXTRACT; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PROTEIN KINASE C; RNA DIRECTED DNA POLYMERASE; TELOMERASE;

ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; APOPTOSIS; AREA UNDER THE CURVE; BASAL CELL CARCINOMA; BLADDER CANCER; CELL DEATH; CLINICAL TRIAL; DEPRESSION; DIAGNOSTIC VALUE; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG ISOLATION; DRUG MECHANISM; DRUG RESEARCH; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALIGNANT MESOTHELIOMA; NONHUMAN; PAIN; PARESTHESIA; PHOTODYNAMIC THERAPY; PHOTOTOXICITY; PRIORITY JOURNAL; REVIEW; SENSITIVITY AND SPECIFICITY; SIDE EFFECT; SQUAMOUS CELL CARCINOMA; TEMPERATURE SENSITIVITY;

ANIMALS; AUSTRIA; CELL DEATH; HUMANS; MOLECULAR STRUCTURE; NEOPLASMS; PERYLENE; PHOTOCHEMOTHERAPY; PHYTOTHERAPY; REPRODUCIBILITY OF RESULTS; VIRUSES;

EID: 11844287615     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/1381612053382287     Document Type: Review

References (167)

1. Agostinis P, Vantieghem A, Merlevede W, de Witte PA. Hypericin in cancer treatment: more light on the way. Int J Biochem Cell Biol 2002;34(3): 221-41.
2. Falk H. From the Photosensitizer Hypericin to the Photoreceptor Stentorin- The Chemistry of Phenanthroperylene Quinones. Angew Chem Int Ed Engl 1999; 38(21): 3116-3136.
3. Miskovsky P. Hypericin - a new antiviral and antitumor photosensitizer: mechanism of action and interaction with biological macromolecules. Curr Drug Targets 2002; 3(1): 55-84.
4. Nathan PJ. Hypericum perforatum (St John's Wort): a non-selective reuptake inhibitor? A review of the recent advances in its pharmacology. J Psychopharmacol 2001; 15(1): 47-54.
5. Barnes J, Anderson LA, Phillipson JD. St John's wort (Hypericum perforatum L.): a review of its chemistry, pharmacology and clinical properties. J Pharm Pharmacol 2001; 53(5): 583-600.
6. Brockmann H, Haschad MN, Maier K, Pohl F. Über das Hypericin, den photodynamisch wirksamen Farbstoff aus Hypericum perforatum. Naturwissenschaften 1939; 32(27): 550.
7. Brockmann H, Pohl F, Maier K, Haschad MN. Über das Hypericin, den photodynamischen Farbstoff des Johanniskrautes (Hypericum perforatum). Annalen der Chemie 1942; 553: 1-52.
8. Brockmann H, Falkenhausen EH, Dorlares A. Die Konstitution des Hypericins. Naturwissenschaften 1950; 37: 540.
9. Altmann R, Falk H. The deprotonation and protonation equilibria of a hypericin derivative in aqueous solution. Monatsh Chem 1997; 128: 571-83.
10. Falk H, Meyer J, Oberreiter M. A convenient semistynthetic route to hypericin. Monatsh Chem 1993; 124: 339-41.
11. Brockmann H, Kluge F, Muxfeldt H. Totalsynthese des Hypericins. Chemische Berichte 1957; 90(2): 2302-18.
12. Falk H, Schoppel G. A Synthesis of Emodin Anthrone. Monatsh Chem 1991; 122: 739-44.
13. Brockmann H, Kluge F. Zur Synthese des Hypericins. Naturwissenschaften 1951; 38(6): 141.
14. Banks HJ, Cameron DW, Raverty WD. Chemistry of the Coccoidea. II* condensed polycyclic pigments from two Australian pseudococcids (Hemiptera). Aust J Chem 1976; 29: 1509-21.
15. Cameron DW, Edmonds JS, Raverty WD. Oxidation of emodin anthrone and stereochemistry of emodin bianthrone. Aust J Chem 1976; 29: 1535-48.
16. Wirz A, Meier B, Sticher O. Absorbance data of hypericin and pseudohypericin used as reference compounds for medicinal plant analysis. Pharmazie 2001; 56(1): 52-7.
17. Falk H, Meyer J. On the homo- and heteroassociation of hypericin. Monatsh Chem 1994; 125: 753-62.
18. Malkin J, Mazur Y. Hypericin derived triplet states and transients in alcohols and water. Photochem Photobiol 1993; 57(6): 929-33.
19. Takahashi I, Nakanishi S, Kobayashi E, Nakano H, Suzuki K, Tamaoki T. Hypericin and pseudohypericin specifically inhibit protein kinase C: possible relation to their antiretroviral activity. Biochem Biophys Res Commun 1989; 165(3): 1207-12.
20. Meruelo D, Lavie G, Lavie D. Therapeutic agents with dramatic antiretroviral activity and little toxicity at effective doses: aromatic polycyclic diones hypericin and pseudohypericin. Proc Natl Acad Sci USA 1988; 85(14): 5230-4.
21. Agostinis P, Vandenbogaerde A, Donella-Deana A, Pinna LA, Lee KT, Goris J, et al. Photosensitized inhibition of growth factor-regulated protein kinases by hypericin. Biochem Pharmacol 1995; 49(11): 1615-22.
22. de Witte P, Agostinis P, Van Lint J, Merlevede W, Vandenheede JR. Inhibition of epidermal growth factor receptor tyrosine kinase activity by hypericin. Biochem Pharmacol 1993; 46(11): 1929-36.
23. Utsumi T, Okuma M, Kanno T, Yasuda T, Kobuchi H, Horton AA, et al. Light-dependent inhibition of protein kinase C and super-oxide generation of neutrophils by hypericin, an antiretroviral agent. Arch Biochem Biophys 1995; 316(1): 493-7.
24. Bruns RF, Miller FD, Merriman RL, Howbert JJ, Heath WF, Kobayashi E, et al. Inhibition of protein kinase C by calphostin C is light-dependent. Biochem Biophys Res Commun 1991; 176(1): 288-93.
25. Frew T, Powis G, Berggren M, Abraham RT, Ashendel CL, Zalkow LH, et al. A multiwell assay for inhibitors of phosphatidylinositol-3-kinase and the identification of natural product inhibitors. Anticancer Res 1994; 14(6B): 2425-8.
26. Baureithel KH, Buter KB, Engesser A, Burkard W, Schaffner W. Inhibition of benzodiazepine binding in vitro by amentoflavone, a constituent of various species of Hypericum. Pharm Acta Helv 1997; 72(3): 153-7.
27. Denke A, Schempp H, Weiser D, Elstner EF. Biochemical activities of extracts from Hypericum perforatum L. 5th communication: dopamine-beta-hydroxylase-product quantification by HPLC and inhibition by hypericins and flavonoids. Arzneimittelforschung 2000; 50(5): 415-9.
28. Kleber E, Obry T, Hippeli S, Schneider W, Elstner EF. Biochemical activities of extracts from Hypericum perforatum L. 1st Communication: inhibition of dopamine-beta-hydroxylase. Arzneimittelforschung 1999; 49(2): 106-9.
29. Schinazi RF, Chu CK, Babu JR, Oswald BJ, Saalmann V, Cannon DL, et al. Anthraquinones as a new class of antiviral agents against human immunodeficiency virus. Antiviral Res 1990; 13(5): 265-72.
30. Tang J, Colacino JM, Larsen SH, Spitzer W. Virucidal activity of hypericin against enveloped and nonenveloped DNA and RNA viruses. Antiviral Res 1990; 13(6): 313-25.
31. Lavie G, Valentine F, Levin B, Mazur Y, Gallo G, Lavie D, Weiner D, et al. Studies of the mechanisms of action of the antiretroviral agents hypericin and pseudohypericin. Proc Natl Acad Sci USA 1989; 86(15): 5963-7.
32. Thomas C, MacGill RS, Miller GC, Pardini RS. Photoactivation of hypericin generates singlet oxygen in mitochondria and inhibits succinoxidase. Photochem Photobiol 1992; 55(1): 47-53.
33. Cott JM. In vitro receptor binding and enzyme inhibition by Hypericum perforatum extract. Pharmacopsychiatry 1997; 30(Suppl 2): 108-12.
34. Bladt S, Wagner H. MAO-Hemmung durch Fraktionen und Inhaltsstoffe von Hypericum-Extrakt. Nervenheilkunde 1993; 12: 349-52.
35. Cott J. Medicinal plants and dietary supplements: sources for innovative treatment or adjuncts? Psychopharmacol Bull 1995; 31(1): 131-7.
36. Suzuki O, Katsumata Y, Oya M, Bladt S, Wagner H. Inhibition of monoamine oxidase by hypericin. Planta Med 1984; 50(3): 272-4.
37. Farnet CM, Wang B, Hansen M, Lipford JR, Zalkow L, Robinson WE Jr, et al. Human immunodeficiency virus type 1 cDNA integration: new aromatic hydroxylated inhibitors and studies of the inhibition mechanism. Antimicrob Agents Chemother 1998; 42(9): 2245-53.
38. Johnson SA, Pardini RS. Antioxidant enzyme response to hypericin in EMT6 mouse mammary carcinoma cells. Free Radic Biol Med 1998; 24(5): 817-26.
39. Simmen U, Higelin J, Berger-Buter K, Schaffner W, Lundstrom K. Neurochemical studies with St. John's wort in vitro. Pharmacopsychiatry 2001; 34(Suppl 1): S137-42.
40. Gobbi M, Moia M, Pirona L, Morizzoni P, Mennini T. In vitro binding studies with two hypericum perforatum extracts - hyperforin, hypericin and biapigenin - on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters. Pharmacopsychiatry 2001; 34(Supp] 1): S45-8.
41. Obach RS. Inhibition of human cytochrome P450 enzymes by constituents of St. John's Wort, an herbal preparation used in the treatment of depression. J Pharmacol Exp Ther 2000; 294(1): 88-95.
42. Budzinski JW, Foster BC, Vandenhoek S, Amason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomedicine 2000; 7(4): 273-82.
43. Wentworth JM, Agostini M, Love J, Schwabe JW, Chatterjee VK. St John's wort, a herbal antidepressant, activates the steroid X receptor. J Endocrinol 2000; 166(3): R11-6.
44. Peebles KA, Baker RK, Kurz EU, Schneider BJ, Kroll DJ. Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum). Biochem Pharmacol 2001; 62(8): 1059-70.
45. Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John's wort. Lancet 2000; 355(9203): 547-8.
46. Ruschitzka F, Meier PJ, Turina M, Luscher TF, Noll G. Acute heart transplant rejection due to Saint John's wort. Lancet 2000; 355(9203): 548-9.
47. Agostinis P, Assefa Z, Vantieghem A, Vandenheede JR, Merlevede W, De Witte P. Apoptotic and anti-apoptotic signaling pathways induced by photodynamic therapy with hypericin. Adv Enzyme Regul 2000; 40: 157-82.
48. Ali SM, Olivo M. Mechanisms of action of phenanthroperylenequinones in photodynamic therapy (review). Int J Oncol 2003; 22(6): 1181-91.
49. Ali SM, Olivo M. Bio-distribution and subcellular localization of Hypericin and its role in PDT induced apoptosis in cancer cells. Int J Oncol 2002; 21(3): 531-40.
50. Ali SM, Olivo M, Yuen GY, Chee SK. Induction of apoptosis by Hypericin through activation of caspase-3 in human carcinoma cells. Int J Mol Med 2001; 8(5): 521-30.
51. Ali SM, Chee SK, Yuen GY, Olivo M. Hypericin and hypocrellin induced apoptosis in human mucosal carcinoma cells. J Photochem Photobiol B 2001; 65(1): 59-73.
52. Ali SM, Chee SK, Yuen GY, Olivo M. Hypericin induced death receptor-mediated apoptosis in photoactivated tumor cells. Int J Mol Med 2002; 9(6): 601-16.
53. Ali SM, Chee SK, Yuen GY, Olivo M. Hypocrellins and Hypericin induced apoptosis in human tumor cells: a possible role of hydrogen peroxide. Int J Mol Med 2002; 9(5): 461-72.
54. Chaloupka R, Obsil T, Plasek J, Sureau F. The effect of hypericin and hypocrellin-A on lipid membranes and membrane potential of 3T3 fibroblasts. Biochim Biophys Acta 1999; 1418(1): 39-47.
55. Oleinick NL, Morris RL, Belichenko I. The role of apoptosis in response to photodynamic therapy: what, where, why, and how. Photochem Photobiol Sci 2002; 1(1): 1-21.
56. Zhang W, Lawa RE, Hintona DR, Su Y, Couldwell WT. Growth inhibition and apoptosis in human neuroblastoma SK-N-SH cells induced by hypericin, a potent inhibitor of protein kinase C. Cancer Lett 1995; 96(1): 31-5.
57. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res 1994; 54(7): 1707-14.
58. Jacobson JM, Feinman L, Liebes L, Ostrow N, Koslowski V, Tobia A, et al. Pharmacokinetics, safety, and antiviral effects of hypericin, a derivative of St. John's wort plant, in patients with chronic hepatitis C virus infection. Antimicrob Agents Chemother 2001; 45(2): 517-24.
59. Kerb R, Brockmoller J, Staffeldt B, Ploch M, Roots I. Single-dose and steady state pharmacokinetics of hypericin and pseudohypericin. Antimicrob Agents Chemother 1996; 40(9): 208-93.
60. Brockmoller J, Reum T, Bauer S, Kerb R, Hubner WD, Roots I. Hypericin and pseudohypericin: pharmacokinetics and effects on photosensitivity in humans. Pharmacopsychiatry 1997; 30(Suppl 2): 94-101.
61. Staffeldt B, Kerb R, Brockmoller J, Ploch M, Roots I. Pharmacokinetics of hypericin and pseudohypericin after oral intake of the hypericum perforatum extract LI 160 in healthy volunteers. J Geriatr Psychiatry Neurol 1994; 7(Suppl 1): S47-53.
62. Gulick RM, McAuliffe V, Holden-Wiltse J, Crumpacker C, Liebes L, Stein DS, et al. Phase I studies of hypericin, the active compound in St. John's Wort, as an antiretroviral agent in HIV-infected adults. AIDS Clinical Trials Group Protocols 150 and 258. Ann Intern Med 1999; 130(6): 510-4.
63. Sattler S, Schaefer U, Schneider W, Hoelzl J, Lehr CM. Binding, uptake, and transport of hypericin by Caco-2 cell monolayers. J Pharm Sci 1997; 86(10): 1120-6.
64. Kamuhabwa AR, Augustijns P, de Witte PA. In vitro transport and uptake of protohypericin and hypericin in the Caco-2 model. Int J Pharm 1999; 188(1): 81-6.
65. Weber ND, Murray BK, North JA, Wood SG. The antiviral agent hypericin has in vitro activity aginst HSV-1 through nonspecific association with viral and cellular membranes. Antivir Chem Chemother 1994; 5: 83-90.
66. Liebes L, Mazur Y, Freeman D, Lavie D, Lavie G, Kudler N, et al. A method for the quantitation of hypericin, an antiviral agent, in biological fluids by high-performance liquid chromatography. Anal Biochem 1991; 195(1): 77-85.
67. Chung PS, Saxton RE, Paiva MB, Rhee CK, Soudant J, Mathey A, et al. Hypericin uptake in rabbits and nude mice transplanted with human squamous cell carcinomas: study of a new sensitizer for laser phototherapy. Laryngoscope 1994; 104(12): 1471-6.
68. Fox E, Murphy RF, McCully CL, Adamson PC. Plasma pharmacokinetics and cerebrospinal fluid penetration of hypericin in nonhuman primates. Cancer Chemother Pharmacol 2001; 47(1): 41-4.
69. Schempp CM, Muller KA, Winghofer B, Schopf E, Simon JC. [St. John's wort (Hypericum perforatum L.). A plant with relevance for dermatology]. Hautarzt 2002; 53(5): 316-21.
70. Kraus GA, Pratt D, Tossberg J, Carpenter S. Antiretroviral activity of synthetic hypericin and related analogs. Biochem Biophys Res Commun 1990; 172(1):149-53.
71. Barnard DL, Huffman JH, Morris JL, Wood SG, Hughes BG, Sidwell RW. Evaluation of the antiviral activity of anthraquinones, anthrones and anthraquinone derivatives against human cytomegalovirus. Antiviral Res 1992; 17(1): 63-77.
72. Andersen DO, Weber ND, Wood SG, Hughes BG, Murray BK, North JA. In vitro virucidal activity of selected anthraquinones and anthraquinone derivatives. Antiviral Res 1991; 16(2): 185-96.
73. Lopez-Bazzocchi I, Hudson JB, Towers GH. Antiviral activity of the photoactive plant pigment hypericin. Photochem Photobiol 1991; 54(1): 95-8.
74. Carpenter S, Kraus GA. Photosensitization is required for inactivation of equine infectious anemia virus by hypericin. Photochem Photobiol 1991; 53(2): 169-74.
75. Hudson JB, Lopez-Bazzocchi I, Towers GH. Antiviral activities of hypericin. Antiviral Res 1991; 15(2): 101-12.
76. Hudson JB, Harris L, Towers GH. The importance of light in the anti-HIV effect of hypericin. Antiviral Res 1993; 20(2): 173-8.
77. Duran N, Song PS. Hypericin and its photodynamic action. Photochem Photobiol 1986; 43(6): 677-80.
78. Knox JP, Dodge AD. Isolation and activity of the photodynamic pigment hypericin. Plant Cell Environ 1985; 8: 19-25.
79. Senthil V, Longworth JW, Ghiron CA, Grossweiner LI. Photosensitization of aqueous model systems by hypericin. Biochim Biophys Acta 1992; 1115(3): 192-200.
80. Lenard J, Rabson A, Vanderoef R. Photodynamic inactivation of infectivity of human immunodeficiency virus and other enveloped viruses using hypericin and rose bengal: inhibition of fusion and syncytia formation. Proc Natl Acad Sci USA 1993; 90(1): 158-62.
81. Stevenson NR, Lenard J. Antiretroviral activities of hypericin and rose bengal: photodynamic effects on Friend leukemia virus infection of mice. Antiviral Res 1993; 21(2): 119-27.
82. Fehr MJ, Carpenter SL, Wannemuehler Y, Petrich JW. Roles of oxygen and photoinduced acidification in the light-dependent antiviral activity of hypocrellin A. Biochemistry 1995; 34(48): 15845-8.
83. Hudson JB, Delaey E, de Witte PA. Bromohypericins are potent photoactive antiviral agents. Photochem Photobiol 1999; 70(5): 820-2.
84. Degar S, Prince AM, Pascual D, Lavie G, Levin B, Mazur Y, et al. Inactivation of the human immunodeficiency virus by hypericin: evidence for photochemical alterations of p24 and a block in uncoating. AIDS Res Hum Retroviruses 1992; 8(11): 1929-36.
85. Degar S, Lavie G, Meruelo D. Photodynamic inactivation of radiation leukemia virus produced from hypericin-treated cells. Virology 1993; 197(2): 796-800.
86. Kraus GA, Melekhov A, Carpenter S, Wannemuhler Y, Petrich J. Phenanthrenequinone antiretroviral agents. Bioorg Med Chem Lett 2000; 10(1): 9-11.
87. Fehr MJ, Carpenter SL, Petrich JW. The role of oxygen in the photoinduced antiviral activity of hypericin. Bioorg Med Chem Lett 1994; 4(11): 1339-44.
88. Park J, English DS, Wannemuehler Y, Carpenter S, Petrich JW. The role of oxygen in the antiviral activity of hypericin and hypocrellin. Photochem Photobiol 1998; 68(4): 593-7.
89. Lavie G, Mazur Y, Lavie D, Prince AM, Pascual D, Liebes L, Levin B, Meruelo D. Hypericin as an inactivator of infectious viruses in blood components. Transfusion 1995; 35(5): 392-400.
90. Prince AM, Pascual D, Meruelo D, Liebes L, Mazur Y, Dubovi E, et al. Strategies for evaluation of enveloped virus inactivation in red cell concentrates using hypericin. Photochem Photobiol 2000; 71(2 : 188-95.
91. Redepenning J, Tao N. Measurement of formal potentials for hypericin in dimethylsulfoxide. Photochem Photobiol 1993; 58(4): 532-5.
92. Kraus GA, Zhang W, Fehr MJ, Petrich JW, Wannemuehler Y, Carpenter S. Research at the interface between chemistry and virology: development of a molecular flashlight. Chem Rev 1996: 96: 523-35.
93. Gai F, Fehr MJ, Petrich JW. Ultrafast excited-state process in the antiviral agent hypericin. J Am Chem Soc 1993; 115: 3384-5.
94. Fehr MJ, McCloskey MA, Petrich JW. Light-induced acidification by the antiviral agent hypericin. J Am Chem Soc 1995; 117: 1833-6.
95. Gai F, Fehr MJ, Petrich JW. Role of solvent in excited-state proton transfer in hypericin. J Phys Chem 1994; 98: 8352-8.
96. Gai F, Fehr MJ, Petrich JW. Observation of excited-state tautomerization in the antiviral agent hypericin and identification of its fluorescent species. J Phys Chem 1994; 98: 5784-95.
97. Petrich JW. Excited-state intramolecular H-atom transfer in nearly symmetrical perylene quinones: hypericin, hypocrellin, and their analogues. Int Rev Phys Chem 2000; 19(3): 479-500.
98. Park J, Datta A, Chowdhury PK, Petrich JW. Is the excited-state H-atom transfer in hypericin concerted? Photochem Photobiol 2001; 73(2): 105-9.
99. Sureau F, Miskovsky P, Chinsky L, Turpin PY. Hypericin-induced cell photosensitization involves an intracelluar pH decrease. J Am Chem Soc 1996; 118: 9484-7.
100. Mirossay A, Mirossay L, Tothova J, Miskovsky P, Onderkova H, Mojzis J. Potentiation of hypericin and hypocrellin-induced phototoxicity by omeprazole. Phytomedicine 1999; 6(5): 311-7.
101. Mirossay L, Mirossay A, Kocisova E, Radvakova I, Miskovsky P, Mojzis J. Hypericin-induced phototoxicity of human leukemic cell line HL-60 is potentiated by omeprazole, an inhibitor of H+K+-ATPase and 5′-(N, N-dimethyl)-amiloride, an inhibitor of Na+/H+ exchanger. Physiol Res 1999; 48(2): 135-41.
102. Thomas C, Pardini RS. Oxygen dependence of hypericin-induced phototoxicity to EMT6 mouse mammary carcinoma cells. Photochem Photobiol 1992; 55(6): 831-7.
103. Diwu Z. Novel therapeutic and diagnostic applications of hypocrellins and hypericins. Photochem Photobiol 1995; 61(6): 529-39.
104. Moraleda G, Wu TT, Jilbert AR, Aldrich CE, Condreay LD, Larsen SH, et al. Inhibition of duck hepatitis B virus replication by hypericin. Antiviral Res 1993; 20(3): 235-47.
105. Hudson JB, Graham EA, Towers GH. Antiviral assays on phytochemicals: the influence of reaction parameters. Planta Med 1994; 60(4): 329-32.
106. Kanofsky JR. Quenching of singlet oxygen by human plasma. Photochem Photobiol 1990; 51(3): 299-303.
107. Cohen PA, Hudson JB, Towers GH. Antiviral activities of anthraquinones, bianthrones and hypericin derivatives from lichens. Experientia 1996; 52(2): 180-3.
108. Carpenter S, Fehr MJ, Kraus GA, Petrich JW. Chemiluminescent activation of the antiviral activity of hypericin: a molecular flashlight. Proc Natl Acad Sci USA 1994; 91(25): 12273-7.
109. Tobin GJ, Ennis WH, Clanton DJ, Gonda MA. Inhibition of bovine immunodeficiency virus by anti-HIV-1 compounds in a cell culture-based assay. Antiviral Res 1996; 33(1): 21-31.
110. Treating AIDS with worts. Science 1991; 254: 522.
111. Steinbeck-Klose A. HIV-negative unter Hypericin oder Leben mit inaktiviertem HIV Virus nach vierjähriger Hypericintherapie? Forsch Komplementarmed 1995; 2: 33-5.
112. Cooper WC, James J. An observational study of the safety and efficacy of hypericin in HIV + subjects [Abstract]: International Conference on AIDS 1990, vol 6, pp 369.
113. Furner V, Bek M, Gold J. A phase I/II unblinded dose ranging study of hypericin in HIV-positive subjects [Abstract]: International Conference on AIDS 1991; vol 7: pp 199.
114. Steinbeck-Klose A, Wernet P. Succesful long term treatment over 40 months of HIV-patients with intravenous hypericin [Abstract]: International Conference on AIDS 1993; vol 9: pp 470.
115. Valentine FT, Itri V, Kudler N, Georgescu R. International Conference on AIDS 1991; vol 7: pp 97.
116. Wen J, Chowdhury P, Wills NJ, Wannemuehler Y, Park J, Kesavan S, et al. Toward the molecular flashlight: preparation, properties, and photophysics of a hypericin-luciferin tethered molecule. Photochem Photobiol 2002; 76(2): 153-7.
117. Corash L, Hanson CV. Photoinactivation of viruses and cells for medical applications. Blood Cells 1992; 18(1): 3-5.
118. Bisaccia E, Berger C, Klainer AS. Extracorporeal photopheresis in the treatment of AIDS-related complex: a pilot study. Ann Intern Med 1990; 113(4): 270-5.
119. Kamuhabwa AR, Agostinis PM, D'Hallewin MA, Baert L, de Witte PA. Cellular photodestruction induced by hypericin in AY-27 rat bladder carcinoma cells. Photochem Photobiol 2001; 74(2): 126-32.
120. Delaey EM, Obermueller R, Zupko I, De Vos D, Falk H, de Witte PA. In vitro study of the photocytotoxicity of some hypericin analogs on different cell lines. Photochem Photobiol 2001; 74(2): 164-71.
121. Andreoni A, Colasanti A, Colasanti P, Mastrocinque M, Ricco P, Roberti G. Laser photosensitization of cells by hypericin. Photochem Photobiol 1994; 59(5): 529-33.
122. VanderWerf QM, Saxton RE, Chang A, Horton D, Paiva MB, Anderson J, et al. Hypericin: a new laser phototargeting agent for human cancer cells. Laryngoscope 1996; 106(4): 479-83.
123. Blank M, Mandel M, Hazan S, Keisari Y, Lavie G. Anti-cancer activities of hypericin in the dark. Photochem Photobiol 2001; 74(2): 120-5.
124. Hamilton HB, Hinton DR, Law RE, Gopalakrishna R, Su YZ, Chen ZH, et al. Inhibition of cellular growth and induction of apoptosis in pituitary adenoma cell lines by the protein kinase C inhibitor hypericin: potential therapeutic application. J Neurosurg 1996; 85(2): 329-34.
125. Couldwell WT, Gopalakrishna R, Hinton DR, He S, Weiss MH, Law RE, et al. Hypericin: a potential antiglioma therapy. Neuro-surgery 1994; 35(4): 705-9; discussion 709-10.
126. Zhang W, Law RE, Hinton DR, Couldwell WT. Inhibition of human malignant glioma cell motility and invasion in vitro by hypericin, a potent protein kinase C inhibitor. Cancer Lett 1997; 120(1): 31-8.
127. Zhang W, Anker L, Law RE, Hinton DR, Gopalakrishna R, Pu Q, et al. Enhancement of radiosensitivity in human malignant glioma cells by hypericin in vitro. Clin Cancer Res 1996; 2(5): 843-6.
128. Hadjur C, Richard MJ, Parat MO, Jardon P, Favier A. Photodynamic effects of hypericin on lipid peroxidation and antioxidant status in melanoma cells. Photochem Photobiol 1996, 64(2): 375-81.
129. Uzdensky AB, Ma LW, Iani V, Hjortland GO, Steen HB, Moan J. Intracellular localisation of hypericin in human glioblastoma and carcinoma cell lines. Lasers Med Sci 2001; 16(4): 276-83.
130. Hadjur C, Richard MJ, Parat MO, Favier A, Jardon P. Photodynamically induced cytotoxicity of hypericin dye on human fibroblast cell line MRC5. J Photochem Photobiol B 1995; 27(2): 139-46.
131. Ugwu F, Vandenbogaerde AL, Merlevede WJ, de Witte PA. A comparative study on the photocytotoxicity of hypericin on A431 cells using three different assays. Anticancer Res 1998; 18(2A): 1181-4.
132. Ochsner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J Photochem Photobiol B 1997; 39(1): 1-18.
133. Schwartz SK, Absolon K, Vermund H. Some relationships of porphyrins, x-rays and tumours. Univ Minn Med Bull 1955; 27: 7-8.
134. Lipson RL, Baldes EJ. The photodynamic properties of a particular haematoporphyrin derivative. Arch Dermatol 1960; 82: 508-16.
135. Dougherty TJ. Activated dyes as anti tumour agents. J Natl Cancer Inst 1974; 52: 1333.
136. Dougherty TJ, Kaufman JE, Goldfarb A, Weishaupt KR, Boyle D, Mittleman A. Photoradiation therapy for the treatment of malignant tumors. Cancer Res 1978; 38(8): 2628-35.
137. Ehrenberg B, Anderson JL, Foote CS. Kinetics and yield of singlet oxygen photosensitized by hypericin in organic and biological media. Photochem Photobiol 1998; 68(2): 135-40.
138. Darmanyan AP, Burel L, Eloy D, Jardon P. Singlet oxygen production by hypericin in various solvents. J Chim Phys 1994;91: 1774-85.
139. Pytel A, Schmeller N. New aspect of photodynamic diagnosis of bladder tumors: fluorescence cytology. Urology 2002; 59(2): 216-9.
140. D'Hallewin MA, De Witte PA, Waelkens E, Merlevede W, Baert L. Fluorescence detection of flat bladder carcinoma in situ after intravesical instillation of hypericin. J Urol 2000; 164(2): 349-51.
141. D'Hallewin MA, Bezdetnaya L, Guillemin F. Fluorescence detection of bladder cancer: a review. Eur Urol 2002; 42(5): 417-25.
142. Olivo M, Lau W, Manivasager V, Tan PH, Soo KC, Cheng C. Macro-microscopic fluorescence of human bladder cancer using hypericin fluorescence cystoscopy and laser confocal microscopy. Int J Oncol 2003; 23(4): 983-90.
143. Chen B, Roskams T, de Witte PA. Antivascular tumor eradication by hypericin-mediated photodynamic therapy. Photochem Photobiol 2002; 76(5): 509-13.
144. Chen B, Xu Y, Roskams T, Delaey E, Agostinis P, Vandenheede JR, et al. Efficacy of antitumoral photodynamic therapy with hypericin: relationship between biodistribution and photodynamic effects in the RIF-1 mouse tumor model. Int J Cancer 2001; 93(2): 275-82.
145. Chen B, Roskams T, de Witte PA. Enhancing the antitumoral effect of hypericin-mediated photodynamic therapy by hyperthermia. Lasers Surg Med 2002; 31(3): 158-63.
146. Alecu M, Ursaciuc C, Halalau F, Coman G, Merlevede W, Waelkens E, et al. Photodynamic treatment of basal cell carcinoma and squamous cell carcinoma with hypericin. Anticancer Res 1998; 18(6B): 4651-4.
147. Kubin A, Kolbabek H, Jindra RH, Dobrovsky W, Alth G, Wierram F. Photodynamic therapy by local application of hypericin - A case report. Res Adv Photochem Photobiol 2000; 1:147-53.
148. Koren H, Schenk GM, Jindra RH, Alth G, Ebermann R, Kubin A, et al. Hypericin in phototherapy. J Photochem Photobiol B 1996; 36(2): 113-9.
149. D'Hallewin MA, Kamuhabwa AR, Roskams T, De Witte PA, Baert L. Hypericin-based fluorescence diagnosis of bladder carcinoma. BJU Int 2002; 89(7): 760-3.
150. Kubin A, Burner U, Loew HG, Wierrani F, Kolbabek H, Alth G. Hypericin complex bound to Polyvinylpyrrolidone (PVP) - a novel therapeutic and diagnostic application? American Society for Photobiology, 31st Annual Meeting. Baltimore 2003; vol 31: pp abstract 226.
151. Kubin A, Loew HG, Burner U, Wierrani F, Kolbabek H, Alth G. Water soluble Hypericin complex bound to Polyvinylpyrrolidone (PVP): 10th Congress of the European Society for Photobiology. Vienna 2003; vol 10: pp abstract P060.
152. Melnik IS, Dets SM, Rusina TV, Denisov NA, Braun EM, Kikot VO, et al. Optical Methods for Tumor Treatment and Detection: Mechanisms and Techniques in Photodynamic Therapy V, in Thomas JD (ed): SPIE - The International Society for Optical Engineering. San Jose, CA, USA, SPIE Proceeding - The International Society for Optical Engineering. 1996; vol 2675: pp 10.
153. Dets SM, Buryi AN, Melnik IS, Joffe AY, Rusina TV. Optical Biopsies and Microscopic Techniques, in Bigio IJ (ed): SPIE - The International Society for Optical Engineering. Vienna, Austria, SPIE - The International Society for Optical Engineering. 1996; vol 2926: pp 43.
154. Miskovsky P, Sureau F, Chinsky L, Turpin PY. Subcellular distribution of hypericin in human cancer cells. Photochem Photobiol 1995; 62(3): 546-9.
155. Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of hypericum extract. J Geriatr Psychiatry Neurol 1994; 7(Suppl 1): S57-9.
156. Delini-Stula A, Lorenz J, Holsboer-Trachsler E. Pflanzliche Antidepressiva. Schweiz Med Forum 2002; 48: 1146-54.
157. Henderson L, Yue QY, Bergquist C, Gerden B, Arlett P. St John's wort (Hypericum perforatum): drug interactions and clinical outcomes. Br J Clin Pharmacol 2002; 54(4): 349-56.
158. Miskovsky P, Chinsky L, Wheeler GV, Turpin PY. Hypericin site specific interactions within polynucleotides used as DNA model compounds. J Biomol Struct Dyn 1995; 13(3): 547-52.
159. Kocisova E, Chinsky L, Miskovsky P. Sequence specific interaction of the antiretrovirally active drug hypericin with 5′ATGGCAGGATAT3′ oligonucleotide: a resonance Raman spectroscopy study. J Biomol Struct Dyn 1998; 15(6): 1147-54.
160. Sanchez-Cortez S, Jancura D, Miskovsky P. Raman spectroscopic study of the interaction of antiretroviraly drug hypericin with nucleic acids. Recent Res Devel in Physical Chem 1997; 1: 359-68.
161. Kocisova E, Chinsky L, Miskovsky P. Sequence specific interaction of the photoactive drug hypericin depends on the structural arrangement and the stability of the structure containing its specific 5AG3 target: a resonance Raman spectroscopy study J Biomol Struct Dyn 1999; 17(1): 51-9.
162. Das K, Smirnov AV, Wen J, Miskovsky P, Petrich JW. Photophysics of hypericin and hypocrellin A in complex with subcellular components: interactions with human serum albumin. Photochem Photobiol 1999; 69(6): 633-45.
163. Hritz J, Kascakova S, Ulicny J, Miskovsky P. Influence of structure of human, rat, and bovine serum albumins on binding properties of photoactive drug hypericin. Biopolymers 2002; 67(4-5): 251-4.
164. Meruelo D, Degar S, Amari N. Mode of action of hypericin as an antiretroviral agent and other relevant findings, in Chu CK, Cutler H (eds): Natural products as antiviral agents. New York, Plenum Press 1992; pp 91-119.
165. Barbaro G, Klatt EC. Highly active antiretroviral therapy and cardiovascular complications in HIV-infected patients. Curr Pharm Design 2003; 9(18): 1475-81.
166. Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis C: an evidence-based approach. Curr Pharm Design 2004; 10(17): 2123-30.
167. Schaffer M, Ertl-Wagner B, Schaffer PM, Kulka U, Hofstetter A, Duhmke E, et al. Porphyrins as radiosensitizing agents for solid neoplasms. Curr Pharm Design 2003; 9(25): 2024-35.